{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-069124","form_type":"8-K","ticker":"CUE","cik":"0001645460","company_name":"Cue Biopharma, Inc.","filed_at":"2025-05-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.179865+00:00","generated_at":"2026-05-21T23:47:34.655811+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Cue Biopharma Q1 net loss $12.3M; announces BI collaboration for CUE-501 and $20M capital raise","bullets":["Net loss $12.3M ($0.17 EPS) vs $12.3M ($0.25) YoY; revenue $0.4M down from $1.7M.","Announced Boehringer Ingelheim collaboration for CUE-501: $12M upfront + up to $345M milestones.","Raised ~$20M gross in follow-on capital raise; received $12M BI upfront in April 2025.","Regained worldwide rights to lead autoimmune program CUE-401; virtual event May 15 with KOLs.","R&D spend $8.5M vs $10.2M YoY; G&A flat at $4.2M; cash $13.1M at Mar 31."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-069124","json":"https://secwatch.observer/filing/0000950170-25-069124.json","markdown":"https://secwatch.observer/filing/0000950170-25-069124.md","text":"https://secwatch.observer/filing/0000950170-25-069124.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1645460/000095017025069124/0000950170-25-069124-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1645460/000095017025069124/cue-20250512.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T23:47:34.655811+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}